TrialReader


Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

NCT01422707 — Early Phase 1, Withdrawn, University of Virginia

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS003)

RegistryNCT01422707
StatusWithdrawn - The study team decided not to pursue this study.
PhaseEarly Phase 1
Study typeInterventional; na, single group, masking: none, basic science
SponsorUniversity of Virginia (Other)
ConditionsHyperandrogenemia, Obesity, Polycystic Ovary Syndrome
InterventionsHydrocortisone (Drug)
Datesstart 2018-01-19, primary completion 2018-07-17, completion 2018-07-17, first posted 2011-08-24, last updated 2018-07-19
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Hyperandrogenemia All trials for Obesity All trials of Hydrocortisone

-Summary

Short term hydrocortisone to test whether improves excess androgen production from adrenal gland and ovaries

Expand all sections  ·  Collapse all

+Detailed description

This study will test whether short-term suppression of adrenal function can ameliorate androgen (male hormone) overproduction in overweight girls with androgen excess. The investigators hypothesize that one month of oral hydrocortisone administration will improve androgen levels in girls with adrenal androgen overproduction. Specifically, this intervention will improve androgen levels after adrenal stimulation testing with adrenocorticotropin hormone (ACTH).

+Arms and interventions

ArmTypeInterventionsDescription
hydrocortisoneExperimentalDrug: Hydrocortisone4 weeks hydrocortisone with pre- and post-intervention Dexamethasone and Cosyntropin to perform standardized adrenal stimulation testing
  • Hydrocortisone (Drug), also known as Cortef: 10 mg/m2/per day PO at bedtime (X4 weeks)

+Outcome measures

Primary outcomes

  • Changes in free testosterone after ACTH administration before and after hydrocortisone administration for 4 weeks [30 and 60 minutes after ACTH, baseline, and after 4 weeks of hydrocortisone administration]

Secondary outcomes

  • Changes in adrenal steroid precursors after ACTH, baseline, and after 4 weeks of hydrocortisone administration [30 and 60 minutes after ACTH, baseline, and after 4 weeks of hydrocortisone administration]

+Eligibility

Sex: Female, ages: 7 Years to 18 Years

Inclusion Criteria:

* Overweight(>85th BMI%) females
* Early to late puberty (expected age range 7-18)
* Hyperandrogenemic (free testosterone greater than 2.5 standard deviations above the mean for normal control subjects of the same Tanner Stage)
* Screening labs within age-appropriate normal range, with the exception of a mildly low hematocrit (see below) and the hormonal abnormalities inherent in obesity which could include mildly elevated luteinizing hormone (LH), lipids, testosterone, prolactin, DHEAS, E2, glucose, and insulin; and decreased follicle-stimulating hormone (FSH) and/or sex hormone-binding globulin (SHBG)

Exclusion Criteria:

* Screening labs outside of age-appropriate normal range
* Hemoglobin <12 mg/dL and hematocrit<36% (Subjects will be offered the opportunity to take iron supplementation for 60 days if their hematocrit is slightly low (33-36%) (suggestive of iron deficiency anemia) and will then return for retesting of their hemoglobin/hematocrit. If still <36%, they will be excluded.)
* Morning Cortisol <5 g/dL
* 17-hydroxyprogesterone >295 ng/dL
* History of Cushing's syndrome or adrenal insufficiency
* Pregnant

+Locations (1)

FacilityCityCountryStatus
University of Virginia Center for Research in ReproductionCharlottesville, VirginiaUnited States

+Investigators

My Notes